Logotype for Smith & Nephew plc

Smith & Nephew (SN) Investor update summary

Event summary combining transcript, slides, and related documents.

Logotype for Smith & Nephew plc

Investor update summary

10 Jun, 2026

Strategic growth, vision, and innovation priorities

  • Focus on four pillars—reach, innovate, scale, and execute efficiently—to drive 6%-7% organic revenue growth and 9%-13% trading profit growth over the next three years, targeting over $1 billion in free cash flow and 12%-13% ROIC by 2028.

  • RISE strategy emphasizes efficient execution, strategic investment, and expanding patient reach to improve margins and returns.

  • Robust product pipeline with increased launch cadence from 2026-2028 across orthopaedics, sports medicine, and wound management.

  • R&D investment is increasing, especially in sports medicine and wound care, with 44 products launched in the past three years and plans for 14-16 new launches annually through 2026.

  • Major scalable technology platforms include MTECH, TESSA, Lumos, and a rapidly evolving robotic platform.

Advanced wound management and innovation

  • Broad portfolio targets high-growth segments like pressure injury prevention, chronic wounds, and surgical site complications, with products such as LEAF, ALLEVYN COMPLETE CARE, and ALLEVYN Ag+ Surgical.

  • LEAF reduces pressure injury risk by 94%, while ALLEVYN COMPLETE CARE offers superior exudate management and flexibility.

  • PICO, a portable single-use negative pressure wound therapy device, reduces surgical site complications by up to 63% and length of stay by 1.75 days.

  • Over 200 patents and 310 studies, including 60 RCTs, support PICO's effectiveness; NICE recommends its use.

  • Continued investment in PICO aims to expand patient reach and accelerate innovation.

Sports medicine and biologics

  • REGENETEN bioinductive implant reduces rotator cuff re-tear rates by 65% at two years and is expanding to extra-articular ligaments.

  • CARTIHEAL AGILI-C implant provides twice the pain reduction of microfracture and reduces risk of knee replacement by over 80%, with durable 5-year outcomes.

  • TESSA introduces real-time, video-based navigation for arthroscopic surgery, enhancing ACL reconstruction accuracy and expanding future applications.

  • Tendon Seam offers stronger, more stable repairs, minimizing gap formation and supporting healing.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more